NT
NTHI.US NeOnc Technologies Holdings, Inc. Common Stock
- Market cap
- USD 142M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NTHI.US undervalued?
Graham numberThe Graham number of NeOnc Technologies Holdings, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NeOnc Technologies Holdings, Inc. Common Stock fundamental analysis
No fundamental analysis for NeOnc Technologies Holdings, Inc. Common Stock yet.
NeOnc Technologies Holdings, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NeOnc Technologies Holdings, Inc. Common Stock
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, …
Full company profileNeOnc Technologies Holdings, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NeOnc Technologies Holdings, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 20.0K | 70.5K | 83.0K | 40.0K | 0.00 |
| Gross Profit | - | 20.0K | 70.5K | 83.0K | 40.0K | -7.86M |
| Operating Income | -3.27M | -2.84M | -12.2M | -7.14M | -58.2M | -35.9M |
| EBITDA | -3.26M | -2.85M | -12.2M | -9.10M | -59.6M | -34.7M |
| Net Income | -3.38M | -3.05M | -14.9M | -11.9M | -62.1M | -36.7M |
| EPS | -0.18 | -0.16 | -0.80 | -0.63 | -3.23 | -1.42 |
| Balance Sheet | ||||||
| Total Assets | 32.5K | 729K | 1.27M | 3.42M | 2.82M | 9.30M |
| Total Liabilities | 2.65M | 2.30M | 15.3M | 8.92M | 20.3M | 22.5M |
| Shareholders' Equity | -2.62M | -1.58M | -14.0M | -5.50M | -17.5M | -13.2M |
| Cash & Short-term Investments | 25.0K | 633K | 31.9K | 64.9K | 58.7K | 6.17M |
| Total Debt | 1.15M | 50.0K | 6.61M | 24.7K | 6.31M | 310K |
| Cash Flow | ||||||
| Operating Cash Flow | -397K | -882K | -1.88M | -4.21M | -20.4M | -22.5M |
| Capital Expenditure | 3.00 | 4.00 | 0.00 | 4.00 | 500K | 8.00 |
| Free Cash Flow | -397K | -882K | -1.88M | -4.21M | -20.9M | -22.5M |
| Ratios | ||||||
| ROA | -10,389.3% | -418.1% | -1,179.2% | -348.2% | -2,200.9% | -394.1% |
| Net Profit Margin | - | -15,233.8% | -21,176.0% | -14,335.5% | -155,404.4% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
NeOnc Technologies Holdings, Inc. Common Stock dividends
NeOnc Technologies Holdings, Inc. Common Stock has not paid dividends in the last 5 fiscal years.
Who owns NeOnc Technologies Holdings, Inc. Common Stock
- Insiders 50.21%
- Institutions 10.94%
- Public & others 38.85%
- Shares outstanding 28.9M
- Free float 8.88M
Top funds holding NTHI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 311K | 1.08% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 57.0K | 0.20% | -30.64% | Sep 2026 |
| iShares Micro-Cap ETF | 32.1K | 0.11% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 26.7K | 0.09% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 24.9K | 0.09% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 17.9K | 0.06% | 0.00% | Aug 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 6.91K | 0.02% | 0.00% | Oct 2026 |
| Vanguard U.S. Eq Idx £ Acc | 4.27K | 0.01% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 2.35K | 0.01% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 542.00 | 0.00% | 0.00% | Sep 2026 |
Top institutions holding NTHI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Cinctive Capital Management LP | 1.61M | 6.20% | +12.76% | Jun 2026 |
| Vanguard Capital Management, LLC | 504K | 1.94% | +133.74% | Jun 2026 |
| Bank of America Corp | 224K | 0.87% | -4.67% | Jun 2026 |
| Westmount Partners, LLC | 197K | 0.76% | +355.17% | Jun 2026 |
| BlackRock Inc | 180K | 0.69% | +15.41% | Jun 2026 |
| Geode Capital Management, LLC | 166K | 0.64% | +30.95% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 91.5K | 0.35% | +63.31% | Jun 2026 |
| State Street Corp | 43.2K | 0.17% | 0.00% | Jun 2026 |
| Northern Trust Corp | 35.9K | 0.14% | +54.14% | Jun 2026 |
| Global Retirement Partners, LLC. | 27.8K | 0.11% | 0.00% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 21.8K | 0.08% | +73.19% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 15.6K | 0.06% | -69.86% | Jun 2026 |
| Royal Bank of Canada | 15.6K | 0.06% | -6.02% | Jun 2026 |
| HCR Wealth Advisors | 15.0K | 0.06% | 0.00% | Jun 2026 |
| Vanguard Global Advisers, LLC | 4.27K | 0.02% | 0.00% | Jun 2026 |
| Ancora Advisors LLC | 2.08K | 0.01% | 0.00% | Jun 2026 |
| Wells Fargo & Co | 2.00K | 0.01% | +33.33% | Jun 2026 |
| UBS Group AG | 1.73K | 0.01% | +534.07% | Jun 2026 |
| Strategic Wealth Partners | 492.00 | 0.00% | 0.00% | Jun 2026 |
| Barclays PLC | 453.00 | 0.00% | -94.38% | Jun 2026 |
NeOnc Technologies Holdings, Inc. Common Stock company profile
- Company name
- NeOnc Technologies Holdings, Inc. Common Stock
- Ticker
- NTHI.US
- Exchange
- USA Stocks
- Listed since
- Mar 26, 2025
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 5
- Fiscal year end
- December
- Address
- 23975 Park Sorrento, Calabasas, CA, United States, 91302
- Phone
- 310 663 7831
- Website
- neonc.com
About NeOnc Technologies Holdings, Inc. Common Stock
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California.
NeOnc Technologies Holdings, Inc. Common Stock management
5- Mr. Amir Farrokh HeshmatpourPresident, CEO, Executive Chairman & Secretary · born 1967
- Dr. Thomas C. Chen M.D., Ph.D.Founder, Chief Medical Officer, Chief Scientific Officer & Vice Chairman · born 1965
- Mr. Keithly A. GarnettChief Financial Officer · born 1975
- Dr. Josh Neman-Ebrahim Ph.D.Chief Clinical Officer · born 1978
- Mr. David Choi Jr.Chief Accounting Officer